loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

As per media sources Dr Reddy’s Laboratories and Emcure Pharma have secured royalty-free

ICICIdirect Research 18 Sep 2026 DISCLAIMER

News: As per media sources Dr Reddy’s Laboratories and Emcure Pharma have secured royalty-free, non-exclusive voluntary licences from Gilead Sciences to manufacture its investigational once-yearly HIV prevention drug, lenacapavir. Dr Reddy’s licence covers 120 low- and lower-middle-income countries with high HIV incidence, with technology transfer and supply planning to follow. Emcure is among five additional manufacturers licensed by Gilead for twice-yearly lenacapavir, alongside Eva Pharma, Ferozsons Laboratories, Hetero and Mylan Laboratories.

View: This could be a sizable opportunity both for Emcure and DRL as both these companies have their own API source as per our knowledge. This is a complex medication with wider expected acceptance due to easy delivery mechanism. WHO is also contemplating using it as a preventive medicine like vaccine. 

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere